ClinicalTrials.gg
CompletedNCT01213043SPARKUpdated May 20, 2013Results posted

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

A Phase 2 interventional study of Prolastin-C, 60 mg/kg and Prolastin-C, 120 mg/kg in Emphysema and Alpha 1-antitrypsin Deficiency (AATD), sponsored by Grifols Therapeutics LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-05-20.

Primary conditionalpha 1-Antitrypsin DeficiencyRegistry: EmphysemaReclassifiedWhy we changed it
Registry
Emphysema — the first condition term the registry derived for this study.
ClinicalTrials.gg
alpha 1-Antitrypsin Deficiency
Why
  1. The study's listed conditions name alpha 1-Antitrypsin Deficiency, a narrower term within Emphysema.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
11th of 25
30 · median 30
Started
2010
with 3 others
Phase 2
6 of 25
none open now
Registered
8th of 25
by date
Lead sponsor
10 of 25
Grifols Therapeutics LLC

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 11th largest by enrollment, is one of 4 that started in 2010, is one of 6 in phase 2, and was the 8th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

This is a study to assess the safety and pharmacokinetics of weekly infusions of 120 mg/kg of Prolastin-C (alpha1-proteinase inhibitor [alpha1-PI] [Human]), compared to weekly infusions of 60 mg/kg of Prolastin-C in patients with alpha 1-antitrypsin deficiency (AATD).

Read the detailed description

The question of whether higher doses of alpha1-PI (>60 mg/kg) are able to provide better protection to patients with alpha 1-antitrypsin deficiency is currently unknown. As a first step to address this question, the present study has been undertaken. This is a multi-center, randomized, double-blind, crossover study to assess the safety and pharmacokinetics of weekly infusions of 120 mg/kg of Prolastin-C, compared to weekly infusions of 60 mg/kg of Prolastin-C in patients with alpha 1-antitrypsin deficiency. This study is a crossover design with 2 treatment sequences:

Treatment Sequence 1: 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg weekly infusion of Prolastin-C for 8 weeks (starting at Week 1) (total of 16 treatment weeks)

Treatment Sequence 2: 120 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (starting at Week 11) (total of 16 treatment weeks)

Approximately 15 subjects are planned to be entered into each treatment sequence.

At Weeks 8 to 11 and Weeks 18 to 21, a total of 15 serial blood samples for each subject will be drawn for pharmacokinetic analysis. The expected duration of the study subject's participation will be approximately 25 weeks (which includes a 3-Week Screening Phase, 2-Week Washout Period [between different alpha-1 PI treatment doses], and a 4-Week Follow-up Period). The following safety parameters will be assessed: adverse events, pulmonary exacerbations, vital signs, pulmonary function tests, and clinical laboratory tests.

03

Conditions studied

  • Emphysema
  • Alpha 1-antitrypsin Deficiency (AATD)

Browse trials for

Keywords

  • emphysema
  • alpha 1-antitrypsin
  • alpha 1-antitrypsin deficiency (AATD)
  • alpha 1-proteinase inhibitor (Alpha-1 PI)
04

In context

alpha 1-Antitrypsin Deficiency Reclassified

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

This study's enrollment of 30 is close to the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

First submitted before Grifols Therapeutics LLC became part of Grifols.

Compared within alpha 1-Antitrypsin Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Emphysema. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 18 and 70 years of age
  • Have a documented diagnosis of congenital AATD
  • Have a post-bronchodilator Forced Expired Volume in 1 second () of ≥30% and \<80% and FEV1/forced vital capacity (FVC) \<70%
  • If receiving alpha-1 PI augmentation therapy, be willing to discontinue the treatment for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Had a moderate or severe pulmonary exacerbation during the 4 weeks before the study
  • History of lung or liver transplant
  • Any lung surgery during the past 2 years
  • Confirmed liver cirrhosis
  • Elevated liver enzymes
  • Severe concurrent disease
  • Females who are pregnant or breast-feeding or unwilling to practice effective during the study
  • Infection with hepatitis A, B, or C, human immunodeficiency or parvovirus B19
  • Smoking during the past 6 months
  • Use of systemic within 4 weeks of the study
  • Use of antibiotics for an exacerbation within 4 weeks of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Prolastin-C, 60 mg/kg

    60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).

    Biological: Prolastin-C, 60 mg/kg

  • Experimental
    Prolastin-C, 120 mg/kg

    120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).

    Biological: Prolastin-C, 120 mg/kg

Interventions

  • BiologicalProlastin-C, 60 mg/kg

    Drug page: Alpha 1-Antitrypsin

    60 mg/kg weekly infusion of Prolastin-C for 8 weeks

    Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), Modified Process, Alpha-1 MP

  • BiologicalProlastin-C, 120 mg/kg

    Drug page: Alpha 1-Antitrypsin

    120 mg/kg weekly infusion of Prolastin-C for 8 weeks

    Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), Modified Process, Alpha-1 MP

07

What researchers measure

Primary outcomes

  1. Subjects With Treatment-Emergent Adverse Events (TEAEs)

    Number of subjects experiencing at least one TEAE. TEAEs were defined as any adverse event (AE) during the study that began on or after the date of first dose of investigational product (i.e., Prolastin-C).

    Time frame: 22 weeks

  2. Subjects With Drug-Related TEAE(s)

    Number of subjects with at least one TEAE that was determined by the Investigator to be either "possibly related" or "related" to the investigational product (i.e., Prolastin-C).

    Time frame: 22 weeks

  3. Subjects With Treatment-Emergent Serious Adverse Events (SAEs)

    Number of subjects who experienced at least one treatment-emergent SAE.

    Time frame: 22 weeks

  4. Subjects Withdrawn Due to an AE(s)

    Number of subjects who were withdrawn from the study due to at least one AE.

    Time frame: 22 weeks

  5. Subjects With Treatment-Emergent Pulmonary Exacerbation(s)

    Number of subjects with at least one treatment-emergent pulmonary exacerbation

    Time frame: 22 weeks

  6. Subjects With Severe TEAE(s) or Pulmonary Exacerbation(s)

    Number of subjects who experienced at least one severe TEAE or pulmonary exacerbation.

    Time frame: 22 weeks

  7. Number of TEAEs

    Total number of TEAEs reported.

    Time frame: 22 Weeks

  8. Number of Drug-related TEAEs

    Total number of drug-related TEAEs reported

    Time frame: 22 Weeks

  9. Number of Treatment-Emergent Pulmonary Exacerbations

    Total number of treatment-emergent pulmonary exacerbations.

    Time frame: 22 Weeks

Secondary outcomes

  1. AUC0-7days

    Area Under the Alpha-1 PI Concentration-Time Curve from Day 0 to Day 7

    Time frame: Week 8 and Week 18 at the following timepoints: 0 (pre-infusion), completion of first infusion bag, completion of 2nd infusion bag, and 15 min, 30 min, and 1, 2, 4, 8, 24, 48, 120, and 168 hours post-dose

  2. Mean Trough

    The average trough concentration at steady-state, calculated as the mean value using the four Trough measurements obtained at Weeks 6, 7, 8 and at 7 days (168 hours) post infusion at Week 8 for the first treatment period or prior to the start of the infusions at Weeks 16, 17, 18, and at 7 days (168 hours) post infusion at Week 18 for the second treatment period.

    Time frame: Single measurment immediately prior to infusion at Weeks 6, 7, 8, 9 and Weeks 16, 17, 18, 19

08

Results

Posted May 20, 2013

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
Milestone60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence
Started1515
Completed1515
Not completed00
Washout Period
Participant flow — Washout Period
Milestone60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence
Started1515
Completed1515
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
Milestone60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence
Started1515
Completed1515
Not completed00
Follow-up
Participant flow — Follow-up
Milestone60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence
Started1515
Completed1515
Not completed00

Outcome measures

PrimarySubjects With Treatment-Emergent Adverse Events (TEAEs)

Number of subjects experiencing at least one TEAE. TEAEs were defined as any adverse event (AE) during the study that began on or after the date of first dose of investigational product (i.e., Prolastin-C).

Time frame:
22 weeks
Reported as:
Number · participants
Subjects With Treatment-Emergent Adverse Events (TEAEs)
participants60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Subjects With Treatment-Emergent Adverse Events (TEAEs)2318
SecondaryAUC0-7days

Area Under the Alpha-1 PI Concentration-Time Curve from Day 0 to Day 7

Time frame:
Week 8 and Week 18 at the following timepoints: 0 (pre-infusion), completion of first infusion bag, completion of 2nd infusion bag, and 15 min, 30 min, and 1, 2, 4, 8, 24, 48, 120, and 168 hours post-dose
Reported as:
Mean · h*mg/mL
AUC0-7days
h*mg/mL60 mg/kg Prolastin-C120 mg/kg Prolastin-C
AUC0-7days203.6 ± 20.48344.8 ± 46.53
Statistical analysis
  • 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C · ANOVA · p = <0.0001 · Geometric least square means ratio: 0.85 · 90% CI 0.83 to 0.88
PrimarySubjects With Drug-Related TEAE(s)

Number of subjects with at least one TEAE that was determined by the Investigator to be either "possibly related" or "related" to the investigational product (i.e., Prolastin-C).

Time frame:
22 weeks
Reported as:
Number · participants
Subjects With Drug-Related TEAE(s)
participants60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Subjects With Drug-Related TEAE(s)31
PrimarySubjects With Treatment-Emergent Serious Adverse Events (SAEs)

Number of subjects who experienced at least one treatment-emergent SAE.

Time frame:
22 weeks
Reported as:
Number · participants
Subjects With Treatment-Emergent Serious Adverse Events (SAEs)
participants60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Subjects With Treatment-Emergent Serious Adverse Events (SAEs)00
PrimarySubjects Withdrawn Due to an AE(s)

Number of subjects who were withdrawn from the study due to at least one AE.

Time frame:
22 weeks
Reported as:
Number · participants
Subjects Withdrawn Due to an AE(s)
participants60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Subjects Withdrawn Due to an AE(s)00
PrimarySubjects With Treatment-Emergent Pulmonary Exacerbation(s)

Number of subjects with at least one treatment-emergent pulmonary exacerbation

Time frame:
22 weeks
Reported as:
Number · participants
Subjects With Treatment-Emergent Pulmonary Exacerbation(s)
participants60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Subjects With Treatment-Emergent Pulmonary Exacerbation(s)75
PrimarySubjects With Severe TEAE(s) or Pulmonary Exacerbation(s)

Number of subjects who experienced at least one severe TEAE or pulmonary exacerbation.

Time frame:
22 weeks
Reported as:
Number · participants
Subjects With Severe TEAE(s) or Pulmonary Exacerbation(s)
participants60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Subjects With Severe TEAE(s) or Pulmonary Exacerbation(s)00
SecondaryMean Trough

The average trough concentration at steady-state, calculated as the mean value using the four Trough measurements obtained at Weeks 6, 7, 8 and at 7 days (168 hours) post infusion at Week 8 for the first treatment period or prior to the start of the infusions at Weeks 16, 17, 18, and at 7 days (168 hours) post infusion at Week 18 for the second treatment period.

Time frame:
Single measurment immediately prior to infusion at Weeks 6, 7, 8, 9 and Weeks 16, 17, 18, 19
Reported as:
Mean · μM
Mean Trough
μM60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Mean Trough17.3 ± 2.3627.7 ± 3.75
PrimaryNumber of TEAEs

Total number of TEAEs reported.

Time frame:
22 Weeks
Reported as:
Number · Events
Number of TEAEs
Events60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Number of TEAEs6943
PrimaryNumber of Drug-related TEAEs

Total number of drug-related TEAEs reported

Time frame:
22 Weeks
Reported as:
Number · Events
Number of Drug-related TEAEs
Events60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Number of Drug-related TEAEs51
PrimaryNumber of Treatment-Emergent Pulmonary Exacerbations

Total number of treatment-emergent pulmonary exacerbations.

Time frame:
22 Weeks
Reported as:
Number · Events
Number of Treatment-Emergent Pulmonary Exacerbations
Events60 mg/kg Prolastin-C120 mg/kg Prolastin-C
Number of Treatment-Emergent Pulmonary Exacerbations96

Adverse events

Collected over Adverse events were assessed from the time of informed consent through the end of study visit; thus, AEs were assessed for up to 25 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
60 mg/kg Prolastin-C—0/30 (0%)15/30 (50%)
120 mg/kg Prolastin-C—0/30 (0%)10/30 (33.3%)
Most frequent other events
Most frequent other events
Event60 mg/kg Prolastin-C120 mg/kg Prolastin-C
COPD ExacerbationRespiratory, thoracic and mediastinal disorders7/305/30
Urinary Tract InfectionInfections and infestations3/300/30
ContusionInjury, poisoning and procedural complications1/302/30
ThrombocytopeniaBlood and lymphatic system disorders2/300/30
ProteinuriaRenal and urinary disorders2/301/30
Blood Creatinine IncreasedInvestigations0/302/30
Blood Glucose IncreasedInvestigations0/302/30

Baseline characteristics

Demographic and other baseline characteristics were analyzed on the intent-to-treat population, which included all subjects who were randomized.

Age Continuous
Age Continuous(years)60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment SequenceTotal
Mean59.7 ± 6.8957.4 ± 6.3458.6 ± 6.62
Sex: Female, Male
Sex: Female, Male(Participants)60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment SequenceTotal
Female8816
Male7714
Race (NIH/OMB)
Race (NIH/OMB)(Participants)60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence120 mg/kg - 60 mg/kg Prolastin-C Treatment SequenceTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White151530
More than one race000
Unknown or Not Reported000
09

Study locations

5 sites
  • University of Florida College of Medicine
    Gainesville, Florida 32610-0225, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Temple University Hosptial/Temple Lung Center
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina, Division of Pulmonary and Critical Care Medicine
    Charleston, South Carolina 29425-6300, United States
  • The University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
10

References and documents

Publications

  • Willis T, Wee K, Mohn G. A high-purity Alpha-1 proteinase inhibitor from human plasma, TAL6004. Proceeding of the 19th European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna, Austria. Abstracts;34:S53.
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Oct 1, 2010
Start
Nov 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
May 20, 2013
Last update
May 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01213043
Responsible party
Sponsor
First posted
Oct 1, 2010
Start date
Nov 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
May 20, 2013
Last update
May 20, 2013

Study contacts

Mark Brantly, MD
principal investigator · University of Florida
Michael Campos, MD
principal investigator · University of Miami
Friedrich Kueppers, MD
principal investigator · Temple University Hospital/Temple Lung Center
James Stocks, MD
principal investigator · The University of Texas Health Science Center at Tyler
Charlie Strange, MD
principal investigator · Medical University of South Carolina, Division of Pulmonary and Critical Care Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion